Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

If simple math and management’s expressed plans for the pipeline timeline moving forward does not reasonably explain how expecting a 10,000% Return On Investment (a 100 bagger) is wishful thinking at best - nothing will. I’ve laid out a reasonable expectation of dilution for the foreseeable future as management chases after super long-shot cancer studies and brain surgery (stroke) with a psychedelic drug. A pertinent and smart question to ask is why aren't you asking management what the hell are they doing about running a speedy Phase 2 clinical trial in North America for Chronic Cough ASAP - 1 year from start to finish(?). Sitting back thinking Moreau has it all figured out shall be a detriment to your cause. It’s obvious from past practice that their timelines are not advantageous to your time and money. They own 2% of the current shares and get paid no matter how the stock performs. When/how do you go about holding them accountable? By expecting someone else to do the heavy lifting or voicing your own concerns? It’s called activism. It’s a myth to think you can’t make a difference. The most logical path to maximizing the market cap with the least amount of shenanigans by management (ohhh there will be plenty more if you let them) is throwing all effort/money at Chronic Cough. Simply consider the fact they believed it was OK to spin the company on a dime and throw nearly all of Algernon’s capital at chasing COVID-19 down a black hole. They knew the odds were incredibly stacked against an underpowered study to reach statistical significance to move to a Phase 3 clinical trial. Moreau finally admitted as much in the lead up to the Final Data Report for COVID-19.Moreau beat the drum of success right up until the Final data readout was imminent. Moreau’s ultimate excuse thereafter was “What If We Had Not…” ran a study for COVID-19?

The guy truly believes he can do no wrong…no wrong that he will ever be held accountable for.

What if management had not run an unpowered study for COVID-19?

The Answer Is Simple:

The company would not have been driven straight over a cliff into the Abyss.

The company would have retained the cash for the Phase 1’s in the pipeline now.

It’s the primary reason for a 100 to 1 reverse split and capital raise at All-time lows.


https://www.scribbr.com/statistics/statistical-power/ -

Can you have statistical significance without power?

If you don't ensure enough power in your study, you may not be able to detect a statistically significant result even when it has practical significance. Your study might not have the ability to answer your research question.Feb 16, 2021

Question - What do you think is going to happen by the time management runs through all of its newly found Phase 1 studies?

Do you think “Everybody Wants In At Phase 2” as stated by Christopher Moreau until blue in the face.

The market didn’t jump in with the Phase 2b/3 COVID-19 study and Moreau jumped up and down in pennyland for attention like he could never duplicate.

Do you think the market will be eager to jump in based on data from a Phase 1 clinical trial for safety only?

The logical course is management will dilute the hell out of Algernon time and again to run any one or more Phase 2 studies for everything currently at Phase 1 - if any of them move forward.

However, the Q3 start of the DMT study appears to be in peril as they have yet to receive the go ahead from the UK.

Has anyone heard anything from Christopher Moreau about that?

Algernon’s leading narrative (DMT) appears to be dying a slow death.

You think that’s something you need to know about sooner rather than later?

Does anybody care?

You need a hit with clinical trial data powered for statistical significance before the next massive dilution scheme - capital raise.

The current path you’re on sets you up yet again as just roadkill.

Live - Learn - Lend A Hand (Take Action).

Have @ It

M$